Pharma scale-up to market: operating model design and investor-readiness

Intensive programme for pharma/biotech scale-ups (TRL 5–9) combining executive guidance on operating model design with structured mentoring for corporate partnerships success. We help you de-risk your scale-up trajectory and build strong relationships with corporates who need what you've built.
Our approach is shaped by senior pharma executives—people who've scaled divisions, managed corporate partnerships, and understand what investors and corporates actually look for in an innovation partner. They advise on readiness and support the execution.
 

Step 1 – Operational Readiness Diagnostic (SORS™)
The programme begins with SORS™ (Startup Operational Readiness Scorecard), a structured assessment of your growth foundations. The output diagnoses your scaling-up risks across all critical dimensions: team & HR, customer management, product development, process scalability, technology infrastructure including AI, financial operations, and legal & compliance. Outcome: Participants receive a roadmap to a successful corporate integration and partnership strategy. 
 

Step 2 – Business Planning
Co-design the organizational and process infrastructure your pharma scale-up needs to grow from validated innovation to market-ready execution. We will pair you up with an executive specialized in pharma, including rare disease and orphan drugs, or biotech. Outcome: Investor-ready operating roadmap. 

Step 3 – Mentoring and Execution
Ongoing 1-on-1 mentoring with senior pharma executives. We embed alongside your team to ensure the roadmap lands with your people and builds the credibility you'll need with corporate partners, investors, and regulators. Focus: governance, team scaling, customer value growth, fundraising readiness, corporate partnership navigation. Outcome: Executable operating model, corporate partnership readiness, closing the execution gap.